Literature DB >> 8831910

Lipids, risk factors and ischaemic heart disease.

W P Castelli1.   

Abstract

Over 200 risk factors for cardiovascular disease (CVD) have now been identified. Among these, the three most important are (1) abnormal lipids, including the fact that there are more than 15 types of cholesterol-containing lipoproteins and four different types of triglyceride-rich particles, some of which are very atherogenic, (2) high blood pressure, and (3) cigarette smoking. In addition, many other factors including diabetes, haemostatic factors such as fibrinogen, factor VII, plasminogen activator inhibitors, and new factors such as apolipoprotein E4 and homocysteine, are known to increase the risk of developing clinical CVD. A low risk for CVD requires that these various factors are present in the circulation in the correct proportions. Two simple tests for determining plasma lipid levels can be used to identify those individuals with an atherogenic lipid profile and who are, therefore, at increased risk for CVD. Firstly, the ratio of total cholesterol to high density cholesterol (HDL cholesterol) should be determined, followed by measurement of plasma triglyceride concentrations. This will allow differentiation of whether the low density lipoproteins (LDL), HDL cholesterol or triglyceride-rich particles such as the small dense beta-very low density lipoproteins (VLDL) are the major cause for concern. Once identified, those individuals with a high lipid risk profile should be treated before, rather than after, experiencing coronary heart disease (CHD).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8831910     DOI: 10.1016/0021-9150(96)05851-0

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  62 in total

1.  Beyond the cholesterol profile: monitoring therapeutic effectiveness of statin therapy.

Authors:  R G Schwartz
Journal:  J Nucl Cardiol       Date:  2001 Jul-Aug       Impact factor: 5.952

Review 2.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 3.  Vascular pleiotropy of statins: clinical evidence and biochemical mechanisms.

Authors:  A S Callahan
Journal:  Curr Atheroscler Rep       Date:  2003-01       Impact factor: 5.113

4.  Measurement of carotid intima-media thickness and carotid plaque detection for cardiovascular risk assessment.

Authors:  Heather M Johnson; James H Stein
Journal:  J Nucl Cardiol       Date:  2011-02       Impact factor: 5.952

5.  Monitoring effectiveness of medical therapy in 2006.

Authors:  Ronald G Schwartz; Mark A Kudes
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

6.  High-density lipoprotein subfractions in normolipidemic individuals without clinical atherosclerosis lipoprotein subfractions in an adult population.

Authors:  Fabio L Sodré; Vera S Castanho; Lucia N Castilho; Silvia de Barros-Mazon; Eliana C de Faria
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

7.  Putting cardiovascular risk into perspective: A view from a pharmacist patient.

Authors:  Tom Smiley
Journal:  Can Pharm J (Ott)       Date:  2013-03

8.  LDL cholesterol performance of beta quantification reference measurement procedure.

Authors:  Masakazu Nakamura; Yuzo Kayamori; Hiroyasu Iso; Akihiko Kitamura; Masahiko Kiyama; Isao Koyama; Kunihiro Nishimura; Michikazu Nakai; Hiroyuki Noda; Mahnaz Dasti; Hubert W Vesper; Yoshihiro Miyamoto
Journal:  Clin Chim Acta       Date:  2014-02-28       Impact factor: 3.786

9.  Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

Authors:  A Colao; S Spiezia; C Di Somma; R Pivonello; P Marzullo; F Rota; T Musella; R S Auriemma; M C De Martino; G Lombardi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  A coronary heart disease risk score based on patient-reported information.

Authors:  Arch G Mainous; Richelle J Koopman; Vanessa A Diaz; Charles J Everett; Peter W F Wilson; Barbara C Tilley
Journal:  Am J Cardiol       Date:  2007-03-13       Impact factor: 2.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.